Ernexa Therapeutics Inc [NASDAQ: ERNA] gained 40.80% or 0.51 points to close at $1.76 with a heavy trading volume of 215172448 shares.
It opened the trading session at $2.175, the shares rose to $2.8599 and dropped to $1.51, the range by which the price of stock traded the whole day. The daily chart for ERNA points out that the company has recorded -43.32% loss over the past six months.
If we look at the average trading volume of 3.40M shares, ERNA reached to a volume of 215172448 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Ernexa Therapeutics Inc [ERNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ERNA shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ERNA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 2.96, with the Price to Cash per share for the same quarter was set at 0.56.
Trading performance analysis for ERNA stock
Ernexa Therapeutics Inc [ERNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 53.04. With this latest performance, ERNA shares gained by 60.73% in over the last four-week period, additionally sinking by -43.32% over the last 6 months – not to mention a drop of -60.09% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ERNA stock in for the last two-week period is set at 71.55, with the RSI for the last a single of trading hit 0.2481, and the three-weeks RSI is set at 0.1730 for Ernexa Therapeutics Inc [ERNA]. The present Moving Average for the last 50 days of trading for this stock 1.2858, while it was recorded at 1.3220 for the last single week of trading, and 2.8400 for the last 200 days.
Ernexa Therapeutics Inc [ERNA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Ernexa Therapeutics Inc [ERNA] shares currently have an operating margin of -2410.45% and a Gross Margin at -19.47%. Ernexa Therapeutics Inc’s Net Margin is presently recorded at -8959.02%.
Ernexa Therapeutics Inc (ERNA) Capital Structure & Debt Analysis
According to recent financial data for Ernexa Therapeutics Inc. ( ERNA), the Return on Equity (ROE) stands at -2264.31%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -161.66%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Ernexa Therapeutics Inc’s Return on Invested Capital (ROIC) is -907.05%, showcasing its effectiveness in deploying capital for earnings.
Ernexa Therapeutics Inc (ERNA) Efficiency & Liquidity Metrics
Based on Ernexa Therapeutics Inc’s (ERNA) latest financial statements, the Debt-to-Equity Ratio is 0.13%, indicating its reliance on debt financing relative to shareholder equity.
Ernexa Therapeutics Inc (ERNA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Ernexa Therapeutics Inc. (ERNA) effectively leverages its workforce, generating an average of -$7286666.67 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.81% and a Quick Ratio of 1.81%, indicating strong ability to cover short-term liabilities.
Ernexa Therapeutics Inc [ERNA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Ernexa Therapeutics Inc posted 0/share EPS, while the average EPS was predicted by analysts to be reported at -37.5/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 37.5. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ERNA.
An analysis of Institutional ownership at Ernexa Therapeutics Inc [ERNA]
There are presently around $0.65%, or 1.61%% of ERNA stock, in the hands of institutional investors. The top three institutional holders of ERNA stocks are: CYPRESS POINT WEALTH MANAGEMENT, LLC with ownership of 94375.0 shares, which is approximately 1.7445%. NAVITER WEALTH, LLC, holding 78796.0 shares of the stock with an approximate value of $$0.14 million in ERNA stocks shares; and NAVITER WEALTH, LLC, currently with $$0.13 million in ERNA stock with ownership which is approximately 1.3457%.
